Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

49.23 -0.13 (-0.26%)
Official Closing Price Updated: 7:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
72 73 Next >
2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains
Investors hunt for new opportunities in stocks that have been discounted & now present promising options for recovery. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Dirt-Cheap Stocks That Could Skyrocket
Low valuations don't always guarantee gains are in the offing. You need a company firing on all cylinders, too. 
Via The Motley Fool
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
From Bristol Myers Squibb
Via Business Wire
Can Bristol Myers Squibb Keep Its Streak Alive?
Bristol Myers Squibb is a $100 billion market cap pharmaceutical company that has raised its dividend every year since 2010 and has paid one since 1933. 
Via Talk Markets
Bristol-Myers Squibb Unusual Options Activity
Via Benzinga
Exploring NYSE:BMY's dividend characteristics.
Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) qualifies as a good dividend investing stock. 
Via Chartmill
Looking Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
Exposures Product Safety
3 stocking stuffers you can buy for yourself
These low-beta, deep-value high-yielding stocks are perfect stocking stuffers, even if you buy them for yourself. Rebound is expected in 2024. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
J&J, Gilead, BMS: A look at undervalued dividend payers
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown 
Via MarketBeat
Why Is Avidity Biosciences (RNA) Stock Up 15% Today?
RNA stock is jumping over 15% in early trading after Avidity announced its expanded alliance with Bristol-Myers Squibb. 
Via InvestorPlace
Why Bristol Myers Squibb Stock Is Fading Today
A high-profile clinical failure by a rival is weighing on the drugmaker's shares today. 
Via The Motley Fool
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Via Benzinga
Why Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?
Avidity Biosciences Inc (NASDAQ: RNA) announced a global licensing and research collaboration with Bristol Myers Squibb & Co (NYSE: BMY) focused on discovering, developing, and commercializing multiple... 
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
3 Resilient Stocks with Massive Potential to Boost Your Wealth
These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life. 
Via InvestorPlace
Don't Wait for a Market Crash: These 2 Top Stocks Are on Sale
Sometimes the stock market offers its own version of Black Friday deals. 
Via The Motley Fool
$1M Bet On Iridium Communications? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Soothing Stocks: 7 Reliable Picks to Ease Your Market Jitters
While circumstances may seem relatively normal now, astute investors may want to consider reliable stocks just in case. 
Via InvestorPlace
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
Dutch Bros (BROS) Stock Gains on JPMorgan Upgrade
Dutch Bros stock is getting a boost on Monday after JPMorgan analyst John Ivankoe weighed in on BROS shares with an upgrade. 
Via InvestorPlace
Uber Stock Falls After Announcement of $1.2 Billion Convertible Notes Offering
Uber stock is moving on Monday as investors react to a $1.2 billion convertible senior notes offering and plans for the funds. 
Via InvestorPlace
Why Is Bristol-Myers Squibb (BMY) Stock Down Today?
Bristol-Myers Squibb stock is falling on Monday as investors in BMY shares react to two updates weighing on the company's stock. 
Via InvestorPlace
Why Is Pharma Giant Bristol-Myers Squibb Stock Trading Lower Today?
Shares of Bristol-Myers Squibb Company (NYSE: BMY) and  2seventy Bio Inc (NASDAQ: TSVT) fell after the companies' efforts to win expanded U.S. 
Via Benzinga
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
2 overlooked stocks that crushed earnings but traded lower
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results 
Via MarketBeat
Exposures Product Safety
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small  
Via Benzinga
Exposures Product Safety
Could Bristol-Myers Squibb Stock Help You Retire A Millionaire?
It isn't exactly a growth stock, but it has a few features that could make you richer. 
Via The Motley Fool
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.